Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07570186

Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants

This study aims to evaluate the effects of food or ethnicity on the pharmacokinetics and safety/tolerability of JPI-547 after a single oral administration in healthy male Korean, Caucasian, and Chinese participants.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Healthy Volunteers

Age range

19 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Seoul National University Hospital

Seoul, South Korea

About this study

  • Cohort 1 is designed to evaluate the effect of food on the pharmacokinetics and safety/tolerability of JPI-547 in healthy Korean and Caucasian participants under fasted and fed conditions.
  • Cohort 2 is designed to explore the effect of ethnicity on the pharmacokinetics and safety/tolerability of JPI-547 in healthy Chinese participants after a single oral administration.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy Korean, Caucasian, or Chinese male participants aged 19 to 50 years at screening
  • Body weight between 50.0 and 90.0 kg and BMI between 18.5 and 29.9 kg/m²
  • Able to understand the study and provide written informed consent
  • Considered suitable for study participation by the investigator based on medical history, physical examination, and clinical laboratory tests

Exclusion criteria

  • Clinically significant medical or surgical history
  • Gastrointestinal disease or surgery affecting drug absorption
  • Hypersensitivity to PARP inhibitors or other significant drug allergy
  • Drug abuse history or positive drug screening
  • Clinically significant abnormal vital signs or laboratory results
  • Positive viral or serologic screening tests
  • Recent use of prohibited medications
  • Recent participation in another clinical trial
  • Recent blood donation or transfusion
  • Inability to abstain from smoking, alcohol, caffeine, or grapefruit
  • Failure to comply with contraception or sperm donation requirements
  • Any condition making the participant unsuitable in the investigator's judgment

Treatment and study plan

JPI-547

Drug

JPI-547 is administered orally as a single dose per administration.

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of JPI-547

    Time frame: Pre-dose through 120 hours post-dose after each administration, based on 17 PK samples per administration; assessed up to Day 20 for the Korean/Caucasian fed/fasted crossover arm and up to Day 6 for the Chinese fasted arm.

    Cmax is defined as the maximum observed plasma concentration of JPI-547 after a single oral administration.

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of JPI-547

    Time frame: Pre-dose through 120 hours post-dose after each administration, based on 17 PK samples per administration; assessed up to Day 20 for the Korean/Caucasian fed/fasted crossover arm and up to Day 6 for the Chinese fasted arm.

    AUClast is defined as the area under the plasma concentration-time curve from time zero to the last quantifiable concentration of JPI-547 after a single oral administration.

  3. Number of Participants With Abnormalities in Safety and Tolerability Assessments

    Time frame: From the first administration of JPI-547 until the Post-Study Visit; assessed up to Day 32 for the Korean/Caucasian fed/fasted crossover arm and up to Day 18 for the Chinese fasted arm.

    Safety and tolerability will be assessed by monitoring adverse events, including subjective and objective symptoms, physical examinations, vital signs, 12-lead electrocardiograms, and clinical laboratory tests after a single oral administration of JPI-547.

Sponsors and collaborators

Lead sponsor

Onconic Therapeutics Inc.

Industry

Registry information

Official study title

A Randomized, Open-label, Single-dose, Crossover Phase 1 Clinical Trial to Evaluate the Effects of Food or Ethnicity on the Pharmacokinetics and Safety/Tolerability of JPI-547 After a Single Oral Administration in Healthy Male Korean, Caucasian and Chinese Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 6, 2026
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.